Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease
Gámez-Valero, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Campdelacreu, Jaume (Hospital Universitari de Bellvitge)
Vilas Rolán, Dolores (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ispierto, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Gascon-Bayarri, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Reñé, Ramón (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Álvarez, Ramiro (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Armengol, Maria P. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Borràs i Serres, Francesc Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Beyer, Katrin (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)

Date:	2021
Abstract:	Dementia with Lewy bodies (DLB) is one of the most common causes of degenerative dementia, after Alzheimer's disease (AD), and presents pathological and clinical overlap with both AD and Parkinson's disease (PD). Consequently, only one in three DLB cases is diagnosed correctly. Platelets, previously related to neurodegeneration, contain microRNAs (miRNAs) whose analysis may provide disease biomarkers. Here, we profiled the whole platelet miRNA transcriptome from DLB patients and healthy controls. Differentially expressed miRNAs were further validated in three consecutive studies from 2017 to 2019 enrolling 162 individuals, including DLB, AD, and PD patients, and healthy controls. Results comprised a seven-miRNA biosignature, showing the highest diagnostic potential for the differentiation between DLB and AD. Additionally, compared to controls, two miRNAs were down-regulated in DLB, four miRNAs were up-regulated in AD, and two miRNAs were down-regulated in PD. Predictive target analysis identified three disease-specific clusters of pathways as a result of platelet-miRNA deregulation. Our cross-sectional study assesses the identification of a novel, highly specific and sensitive platelet-associated miRNA-based biosignature, which distinguishes DLB from AD.
Grants:	Ministerio de Economía y Competitividad PI15/00216 Instituto de Salud Carlos III PI18/00276
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Alzheimer disease ; Dementia with Lewy bodies ; Mirna ; Peripheral biomarkers ; Platelets ; Synucleinopathies
Published in:	Biomedicines, Vol. 9 (september 2021) , ISSN 2227-9059

DOI: 10.3390/biomedicines9091272
PMID: 34572457

19 p, 2.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles